Esperion Therapeutics (ESPR) Lifted to Strong-Buy at BidaskClub
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.
Several other research analysts also recently weighed in on ESPR. Bank of America raised shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 target price for the company in a research note on Friday, January 5th. Northland Securities restated a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Chardan Capital restated a “neutral” rating and issued a $75.00 price target (up previously from $20.00) on shares of Esperion Therapeutics in a report on Tuesday, December 5th. Finally, Needham & Company LLC upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and lifted their price target for the company from $72.00 to $81.00 in a report on Thursday, December 14th. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $62.08.
Esperion Therapeutics (NASDAQ:ESPR) opened at $73.26 on Friday. Esperion Therapeutics has a one year low of $10.71 and a one year high of $74.95. The firm has a market cap of $1,910.00, a PE ratio of -10.68 and a beta of 2.73.
In other news, Director Nicole Vitullo sold 9,326 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total transaction of $502,205.10. Following the completion of the sale, the director now owns 2,472 shares in the company, valued at approximately $133,117.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 32.50% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the company. Meditor Group Ltd boosted its holdings in Esperion Therapeutics by 1.2% in the 4th quarter. Meditor Group Ltd now owns 2,322,835 shares of the biopharmaceutical company’s stock worth $152,935,000 after acquiring an additional 27,900 shares during the period. Iguana Healthcare Management LLC boosted its holdings in Esperion Therapeutics by 50.0% in the 3rd quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the biopharmaceutical company’s stock worth $7,518,000 after acquiring an additional 50,000 shares during the period. California Public Employees Retirement System boosted its holdings in Esperion Therapeutics by 14.9% in the 3rd quarter. California Public Employees Retirement System now owns 48,158 shares of the biopharmaceutical company’s stock worth $2,414,000 after acquiring an additional 6,258 shares during the period. Perceptive Advisors LLC purchased a new position in Esperion Therapeutics in the 3rd quarter worth approximately $540,000. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in Esperion Therapeutics in the 3rd quarter worth approximately $12,583,000. Institutional investors and hedge funds own 92.24% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Esperion Therapeutics (ESPR) Lifted to Strong-Buy at BidaskClub” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/esperion-therapeutics-espr-lifted-to-strong-buy-at-bidaskclub/1805128.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.